Form 4: Exelixis Executive Exercises Performance-Based Stock Units, Gains 118,780 Shares

Exelixis' EVP & General Counsel, Jeffrey Hessekiel, acquired 118,780 shares of common stock following the vesting of performance-based restricted stock units.

Summary

• Jeffrey Hessekiel, EVP & General Counsel at Exelixis, Inc., acquired 118,780 shares of common stock on January 16, 2025, due to the vesting of performance-based restricted stock units (PSUs).
• The vesting was triggered by the Compensation Committee's certification that certain performance criteria had been met.
• The PSUs were initially granted on March 4, 2022, and allowed for vesting of up to 175% of the target shares based on performance.
• 50% of the achieved shares vested immediately on January 16, 2025, and the remaining 50% will vest on February 15, 2026, contingent on continued service.
• Additionally, 26,289 shares were withheld to cover taxes related to the vesting.
• Hessekiel also holds 563,550 shares directly and an unspecified amount indirectly through a 401(k) plan.

Sentiment

Score: 7

Explanation: The document reflects a positive event for the executive and indicates that the company has met certain performance criteria. However, it is a routine filing and does not contain any major surprises.

Positives

• The vesting of performance-based stock units indicates that the company has met certain performance criteria.
• The executive's increased shareholding aligns his interests with those of the shareholders.
• The vesting of the PSUs is a reward for the executive's performance and contribution to the company.

Negatives

• The withholding of 26,289 shares to cover taxes reduces the total number of shares received by the executive.

Risks

• The future vesting of the remaining 50% of the shares is contingent on the executive's continued service, which introduces a risk of forfeiture if the executive leaves the company before February 15, 2026.

Future Outlook

The remaining 50% of the achieved shares will vest on February 15, 2026, subject to the executive's continued service.

Industry Context

This filing is a routine disclosure of executive stock transactions, which is common in publicly traded companies. It reflects the company's compensation practices and the alignment of executive interests with shareholder value.

Comparison to Industry Standards

• Performance-based equity awards are a common practice in the biotechnology industry to incentivize executives and align their interests with company performance.
• The vesting schedule of the PSUs, with a portion vesting upon performance achievement and the remainder vesting later, is a typical structure.
• Companies like Gilead Sciences and Amgen also use similar equity-based compensation plans for their executives.

Stakeholder Impact

• Shareholders may view the vesting of performance-based stock units as a positive sign of the company's performance.
• The executive's increased shareholding aligns his interests with those of the shareholders.

Next Steps

• The remaining 50% of the achieved shares will vest on February 15, 2026, subject to the executive's continued service.

Key Dates

Keywords

Exelixis, stock, vesting, performance-based, restricted stock units, PSU, executive, shares, compensation, equity